Literature DB >> 15248064

Small-cell carcinoma of the urinary bladder. A clinico-pathological study of ten cases.

P Soriano1, S Navarro, M Gil, A Llombart-Bosch.   

Abstract

Small-cell carcinoma (SCC) of the urinary bladder is an infrequent neoplasia accounting for 0.5% of all tumors located at this level. There is a predilection for males over females with a 4:1 proportion and a median age of 66 years. In most cases, the initial diagnosis is made at the metastatic or progressive stage of the disease. For this study, we collected ten cases of SCC of the urinary bladder, diagnosed over a period of 16 years, to describe the morphological and immunocytochemical characteristics of these infrequent neoplasia. In all cases, clinical data such as age at presentation, personal background, clinical symptoms, stage, treatment, clinical outcome and present status were available. Primary antibodies included chromogranin, neuron-specific enolase, synaptophysin, PGP 9.5, HNK-1, cytokeratin 34betaE12, cytokeratin 20, thyroid transcription factor-1 (TTF-1), c-erbB2 (CB-11), p53 (DO7), and Ki67 (MIB-1). In addition to the expression of neural/neuroendocrine markers, immunostaining for p53 and c-erbB2 was found in 80% and 50% of cases, respectively. In this paper, we confirm the aggressive course of the neoplastic disease. The expression of c-erbB2 in 50% of cases opens up hypothetical new possibilities for the use of immunotherapy in such cases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15248064     DOI: 10.1007/s00428-004-1041-1

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  41 in total

1.  Small cell neuroendocrine carcinoma of the urinary bladder. A clinicopathologic study with emphasis on cytologic features.

Authors:  S Z Ali; V E Reuter; M F Zakowski
Journal:  Cancer       Date:  1997-01-15       Impact factor: 6.860

2.  Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.

Authors:  Charles L Vogel; Melody A Cobleigh; Debu Tripathy; John C Gutheil; Lyndsay N Harris; Louis Fehrenbacher; Dennis J Slamon; Maureen Murphy; William F Novotny; Michael Burchmore; Steven Shak; Stanford J Stewart; Michael Press
Journal:  J Clin Oncol       Date:  2002-02-01       Impact factor: 44.544

3.  Chromosomal imbalances in small cell carcinomas of the urinary bladder.

Authors:  L Terracciano; J Richter; L Tornillo; L Beffa; P A Diener; R Maurer; T C Gasser; H Moch; M J Mihatsch; G Sauter
Journal:  J Pathol       Date:  1999-10       Impact factor: 7.996

4.  Immunohistochemical analysis of the proliferative activity of neuroendocrine tumors from various organs. Are there indications for a neuroendocrine tumor-carcinoma sequence?

Authors:  B Helpap; J Köllermann
Journal:  Virchows Arch       Date:  2001-01       Impact factor: 4.064

5.  Immunostaining for thyroid transcription factor 1 and cytokeratin 20 aids the distinction of small cell carcinoma from Merkel cell carcinoma, but not pulmonary from extrapulmonary small cell carcinomas.

Authors:  W Cheuk; M Y Kwan; S Suster; J K Chan
Journal:  Arch Pathol Lab Med       Date:  2001-02       Impact factor: 5.534

6.  High-risk human papillomavirus infections and overexpression of p53 protein as prognostic indicators in transitional cell carcinoma of the urinary bladder.

Authors:  M Furihata; K Inoue; Y Ohtsuki; H Hashimoto; N Terao; Y Fujita
Journal:  Cancer Res       Date:  1993-10-15       Impact factor: 12.701

7.  Small cell carcinoma of the urinary bladder. A clinicopathologic analysis of 22 cases.

Authors:  D J Grignon; J Y Ro; A G Ayala; D T Shum; N G Ordóñez; C J Logothetis; D E Johnson; B Mackay
Journal:  Cancer       Date:  1992-01-15       Impact factor: 6.860

8.  Undifferentiated small-cell carcinoma of the urinary bladder: report of two cases with a primary urinary cytodiagnosis.

Authors:  L Borghi; E Bianchini; G Altavilla
Journal:  Diagn Cytopathol       Date:  1995-07       Impact factor: 1.582

9.  Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression.

Authors:  A S Sarkis; G Dalbagni; C Cordon-Cardo; Z F Zhang; J Sheinfeld; W R Fair; H W Herr; V E Reuter
Journal:  J Natl Cancer Inst       Date:  1993-01-06       Impact factor: 13.506

10.  p53 immunohistochemistry in transitional cell carcinoma and dysplasia of the urinary bladder correlates with disease progression.

Authors:  Y Soini; T Turpeenniemi-Hujanen; D Kamel; H Autio-Harmainen; J Risteli; L Risteli; K Nuorva; P Pääkkö; K Vähäkangas
Journal:  Br J Cancer       Date:  1993-11       Impact factor: 7.640

View more
  10 in total

1.  Small cell carcinoma of the urinary bladder without gross hematuria: a case report.

Authors:  Wanqiu Huang; Yang Luan; Lu Jin; Tao Wang; Ruibao Chen; Zheng Liu; Zhiqiang Chen; Ruzhu Lan
Journal:  Front Med       Date:  2015-08-13       Impact factor: 4.592

2.  Management of small cell carcinoma of the bladder: Consensus guidelines from the Canadian Association of Genitourinary Medical Oncologists (CAGMO).

Authors:  Patricia Moretto; Lori Wood; Urban Emmenegger; Normand Blais; Som Dave Mukherjee; Eric Winquist; Eric Charles Belanger; Robert Macrae; Alexander Balogh; Ilias Cagiannos; Wassim Kassouf; Peter Black; Piotr Czaykowski; Joel Gingerich; Scott North; Scott Ernst; Suzanne Richter; Srikala Sridhar; M Neil Reaume; Denis Soulieres; Andrea Eisen; Christina M Canil
Journal:  Can Urol Assoc J       Date:  2013 Jan-Feb       Impact factor: 1.862

3.  The oncological outcomes of small cell carcinoma of the bladder.

Authors:  Harley A Williams; Nahid Punjani; Obaidullah Khan; Nicholas E Power
Journal:  Can Urol Assoc J       Date:  2018-12-03       Impact factor: 1.862

4.  HNK-1 glycan functions as a tumor suppressor for astrocytic tumor.

Authors:  Misa Suzuki-Anekoji; Masami Suzuki; Tatsuya Kobayashi; Yoshiko Sato; Jun Nakayama; Atsushi Suzuki; Xingfeng Bao; Kiyohiko Angata; Minoru Fukuda
Journal:  J Biol Chem       Date:  2011-07-22       Impact factor: 5.157

5.  TTF1 expression in normal lung neuroendocrine cells and related tumors: immunohistochemical study comparing two different monoclonal antibodies.

Authors:  Stefano La Rosa; Anna Maria Chiaravalli; Claudia Placidi; Nikolaos Papanikolaou; Michele Cerati; Carlo Capella
Journal:  Virchows Arch       Date:  2010-08-06       Impact factor: 4.064

6.  Prognostic significance of serum neuron-specific enolase in small cell carcinoma of the urinary bladder.

Authors:  Akihiro Naito; Satoru Taguchi; Tohru Nakagawa; Akihiko Matsumoto; Yasushi Nagase; Mariko Tabata; Jimpei Miyakawa; Motofumi Suzuki; Hiroaki Nishimatsu; Yutaka Enomoto; Shintaro Takahashi; Toshikazu Okaneya; Daisuke Yamada; Takamitsu Tachikawa; Shigeru Minowada; Tetsuya Fujimura; Hiroshi Fukuhara; Haruki Kume; Yukio Homma
Journal:  World J Urol       Date:  2016-05-14       Impact factor: 4.226

Review 7.  Neuroendocrine Tumors of the Urinary Bladder According to the 2016 World Health Organization Classification: Molecular and Clinical Characteristics.

Authors:  Erik Kouba; Liang Cheng
Journal:  Endocr Pathol       Date:  2016-09       Impact factor: 3.943

8.  Clinicopathologic and Immunohistochemical Study of Combined Small Cell Carcinoma and Urothelial Carcinoma Molecular Subtype.

Authors:  Guang-Qian Xiao; Mary M Barrett; Qi Yang; Pamela D Unger
Journal:  Pathol Oncol Res       Date:  2017-12-16       Impact factor: 3.201

9.  Clinical outcome of primary small cell carcinoma of the urinary bladder.

Authors:  Chen-Pang Hou; Yu-Hsiang Lin; Chien-Lun Chen; Phei-Lang Chang; Ke-Hung Tsui
Journal:  Onco Targets Ther       Date:  2013-08-26       Impact factor: 4.147

Review 10.  Small-cell carcinoma of the urinary bladder: where do we stand?

Authors:  Liviu Ghervan; Andreea Zaharie; Bogdan Ene; Florin I Elec
Journal:  Clujul Med       Date:  2017-01-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.